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1. Introduction 
Menopause represents the final stage of the continuous process of reproductive aging in a 
woman’s life, marking the end of her fertility. According to the World Health Organization 
(WHO), the natural menopause is defined as the permanent cessation of menstruation resulting 
from the loss of ovarian follicular activity (WHO Report, 1996). Preceded by endocrine and 
menstrual cycle changes described as “menopausal transition”, natural menopause occurs at 
an average age of approximately 51 years, although a high inter-individual variability is 
supported by results from epidemiological studies. However, occurrence of menopause 
outside the estimated normal age interval (45-55 years) is associated with increased morbidity, 
either when a late or on the contrary, a premature cessation of menstruation appears. A late 
menopause implies a longer exposure to estrogens and a possible increased risk for breast 
(Colditz, 1993; Kelsey & Bernstein, 1996) and endometrial cancer (Dossus et al., 2010; 
McPherson et al., 1996) or for venous thromboembolism (Simon et al., 2006). On the other 
hand, women entering menopause earlier are facing a hypo-estrogenic state for a longer 
period compared to women undergoing normal menopause. That is the case for about 1% of 
women, which are confronted with the diagnosis of primary ovarian insufficiency (POI). POI 
is defined by the presence of amenorrhea associated with elevated follicle-stimulating 
hormone (FSH) levels in the menopausal range in women younger than 40 years (Bachelot et 
al., 2009). Women facing a premature cessation of the ovarian function were shown to be at 
increased risk for premature death, cardiovascular disease, neurologic disease, mood 
disorders, osteoporosis or psychosexual dysfunction (Shuster et al., 2010). As the main 
rationale for these disorders was linked to hormonal changes, maintaining a certain level of 
ovarian steroids for a given period of time arose as an essential condition for conserving life 
quality in women (Wilson, [1966]). Accentuated by the increasing life span, researches related 
to menopause and its treatment have provided scientific community with an increased body of 
data during the last decades. However, different aspects regarding the benefit/risk balance or 
the ideal doses and routes of administration of hormone replacement therapy (HRT) in 
menopausal women remain uncertain (Grodstein et al., 1997; Rossouw et al., 2002). 
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In this context, our paper addresses various issues related to steroid hormone substitution, 
ranging from the basic pharmacology of sex steroids to their clinical use in HRT and 
subsequent benefits and risks.  
2. Sex steroids 
2.1 Natural oestrogens and progestogens 
During a woman’s reproductive lifetime, sex steroids (Oestrogens and Progestogens - the 
two main classes of female steroids) result mainly from the process of ovarian 
steroidogenesis and only small amounts are being secreted by the peripheral compartments 
(e.g. adrenals, adipose tissue). This characteristic is maintained until menopause, when 
subsequent to a decline in ovarian synthesis, sex steroid plasmatic levels rely only to the less 
significant amounts produced peripherally. In the particular case of pregnant women, the 
pivotal role for steroid secretion shifts from ovaries to placenta.  
Ovarian secretion of sex steroids during reproductive age follows a monthly cyclic evolution 
under the control of pituitary gonadotropins (Figure 1A). This precise central control of the 
ovarian function depends on the coordinated pulsatile secretions of the hypothalamic  
GnRH  (Bouligand et al., 2009) and of pituitary gonadotropins. The decrease in sex steroids 
levels in menopause abolishes the normal negative feedback at the hypothalamus and 
pituitary glands, resulting in an over-secretion of gonadotropins, especially FSH (Figure 1B).  
The pharmacological basis of hormone replacement therapy is to compensate the decrease 
of estradiol production by ovaries in order to limit the adverse events due to sex steroids 
deficiency.   
  
Fig. 1. The Hypothalamic-Pituitary-Gonadal (HPG) axis in women. A. Characteristics of 
HPG axis during the reproductive age. B. Changes in HPG axis following menopause.   
Among the three forms of natural circulating oestrogens (i.e. estradiol, estriol and estrone, 
Figure 2), the main biological effect is exerted by estradiol, with a potency of approximately 
ten times that of estrone (Coldham et al., 1997; Van den Belt et al., 2004), while estriol 
exhibits the weakest estrogenic activity. In the second class of female sex steroids, 
progesterone represents the most important component, with significantly higher secreted 
levels than 17-hydroxyprogesterone, the other naturally occurring progestogen (Figure 2).  
B.A. 
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Fig. 2. Chemical Structure of Natural Sex Steroids 
2.2 Mechanisms of action of sex steroids 
The mechanisms by which oestrogen and progesterone exert their effects are complex 
(Figure 3A), and involve both classic pathways of hormone gene transcription through their 
cognate receptors, as well as “non-genomic” actions, the latter being characterized by 
significantly faster response rates (e.g. seconds, minutes).  
 
SH: steroid hormones (oestrogen, progesterone) ; SR: steroid receptor (ER, PR) ; enSR: extranuclear steroid 
receptors ; HSP: heat shock proteins ; HRE: hormone response elements.  
Fig. 3.a. Sex steroids mechanism of action  
Oestradiol and progesterone receptors (ERs and PRs respectively) belong to the large family 
of nuclear receptors (NRs), sharing several structural features (Loosfelt et al., 1986) and 
acting as transcriptional factors in a ligand dependent manner (For review, (Edwards, 2005). 
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Two major forms have been identified for each of the two types of ovarian steroid receptor, 
namely ER┙ and ER┚ (Kuiper et al., 1996; Walter et al., 1985), and PR-A and PR-B 
respectively (Conneely et al., 1989; Huckaby et al., 1987; Kastner et al., 1990; Khan et al., 
2011) (Figure 3B). 
LBDDBD H
LBDDBD H
LBDDBD H
LBDDBD H
-COOH
-COOH
-COOH
-COOH
NH2-
NH2-
NH2-
NH2-
ERa
ERß
17% 96% 54%
PR-B
PR-A
AF1 AF2
AF1 AF2AF3
100%
933 a.a.
769 a.a.
595 a.a.
530 a.a.
 
LBD: ligand binding domain; DBD: DNA binding domain; AF: transcription activation domain (AF-1, AF-2, 
AF-3); H: Hinge region, a.a. : amino-acids. The percentages indicate the amino acid identity between domains of 
ER┙ and ER┚ and between A and B forms of PR.  
Fig. 3.b. Domain structures of estrogen (ER) and progesterone (PR) receptors.  
Most of ERs and PRs are constitutively localized in the nucleus in the absence of their 
ligands (Welshons et al., 1985), and nuclear localization signals have been described in the 
hinge region (Guiochon-Mantel et al., 1989; Picard et al., 1990). Due to their lipophilic 
nature, steroids will easily cross the cell membrane and bind to specific receptors, resulting 
in hormone-receptor complexes. Prior to ligand binding, receptors are inactive and associate 
protein complexes, among which the heat shock proteins (hsp) play important roles (e.g. hsp 
90, hsp 70)(Pratt & Toft, 1997). But in the presence of their ligands, receptors undergo 
conformational changes with subsequent release of the associated protein complexes and 
bind to specific DNA sequences (hormone-response elements) from the promoter regions of 
target genes. The expression of target genes is thus modulated after interaction with various 
coregulators (Rosenfeld & Glass, 2001; Amazit et al., 2011). ERs and PRs bind DNA as 
dimers and have the ability to form both homodimers and heterodimers (ER┙/┚, PRA/B 
respectively)(Cowley et al., 1997; Leonhardt et al., 1998). Furthermore, the complexity of 
oestrogen and progesterone actions is enhanced by the growing body of evidence 
supporting the non-genomic mechanisms of steroid hormones action (Hammes & Levin, 
2007; Levin, 2011; Losel & Wehling, 2003). These rapid effects may not be explained by the 
classic pathway and involve a variety of signalling events, such as the activation of various 
kinases, ion channels regulation and intracellular calcium mobilization or nitric oxide 
synthesis (Edwards, 2005; Madak-Erdogan et al., 2008). Responsible for generating these 
effects may be either membrane forms of classically ERs and PRs or alternative unrelated 
molecules (Wendler et al., 2010).   
2.3 Physiological effects  
Oestrogens and progestogens main effects concern the reproductive organs, initiating and 
supporting their development and functionality. Secondary sex characteristics are under the 
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close control of gonadal steroids. During the reproductive lifetime of a woman, oestrogens 
dictate the proliferation of the uterine endometrium and the development of endometrial 
glands, while progesterone promotes secretory changes of the endometrium, in a process of 
preparation of the ideal milieu for implantation of the fertilized ovum. In the breast, 
oestrogens promote the development of the stromal and ductal systems together with fat 
deposition at this level, and progesterone induces the development of the secretory units of 
the breast, causing alveolar cells to proliferate.  
Although the reproductive system represents the principal target for sex steroids, their 
effects are far from being limited only to this system. Bone health, for instance, is greatly 
influenced by oestrogens levels, as they play an important role in the process of bone 
remodelling. Under their action, skeletal resorption is diminished due to a decreased 
osteoclastic activity and by consequence, bone formation is promoted. Furthermore, a 
cardioprotective role exerted by ovarian steroids was inferred due to the significantly lower 
rates of cardiovascular diseases manifested by women prior to menopause compared to 
men and the cancelation of these gender differences following menopause. Several 
metabolic effects are also described, oestrogens slightly increasing the metabolic rate, 
promoting deposition of the fat in subcutaneous tissue and changing lipoprotein profiles by 
increasing HDL and decreasing LDL cholesterol (Edwards, 2005; Guyton & Hall, c2006). 
3. Menopause principal consequences  
Given the multitude of physiological effects exerted by sex steroids in women, it is not 
surprising that the hormonal changes related to menopause have been linked to a wide 
spectrum of symptoms and disorders. The most frequent menopausal symptoms include 
vasomotor disorders (e.g. hot flashes, night sweets), urogenital atrophy (e.g. vaginal 
dryness, urinary symptoms), or psychological disturbances (e.g. sleep disturbances, 
forgetfulness, mood changes or depression), all of which may seriously impact on women’s 
quality of life. Decreased oestrogen levels in menopause result in an altered bone structure 
with reduced bone mineral density (BMD) and increased risk for subsequent fractures. 
Postmenopausal women, compared to the premenopausal period,   are also more prone to 
develop cardiovascular disease (CVD), which represents the leading cause of death in 
women. Furthermore, the increased risk of dementia and Alzheimer disease in 
postmenopausal women was also partially attributed to endogenous oestradiol depletion 
(Yaffe et al., 2007). 
If the aforementioned effects are present in women undergoing natural menopause, the 
magnitude of these consequences is even higher in POI women and the dimension of each 
long-term effect may vary in relation to the exact cause of POI and to the rapidity of 
apparition of the oestrogen deficit (e.g. women undergoing surgical oophorectomy will face 
a sudden decrease in steroids levels compared to women experiencing a spontaneous POI) 
(Maclaran et al., 2010). All-cause mortality rates in women appear to be associated with age 
at menopause, women entering menopause before 40 years having mortality rates twice as 
the ones seen in the 50-54 years group (Snowdon et al., 1989). Studies on the cardiovascular 
risk in POI demonstrated that several risk factors for CVD are influenced by a premature 
occurence of menopause (e.g. alteration of lipid profiles (Knauff et al., 2008), decreased 
insulin sensitivity(Corrigan et al., 2006) or the presence of metabolic syndrome (Eshtiaghi et 
www.intechopen.com
 Pharmacology 
 
318 
al., 2010)). Moreover, the impaired endothelial function found in women with POI, 
precursor of more severe vascular abnormalities, was improved by hormonal replacement, 
further supporting the role of steroids in normal cardiovascular function (Kalantaridou et 
al., 2004). POI patients present with low BMD, which seems to be greatly influenced by the 
accelerated bone loss during the first 4-5 years of menopause (Amarante et al., 2011; Anasti 
et al., 1998; Gallagher, 2007; Uygur et al., 2005; van Der Voort et al., 2003), and hence having 
an increased risk of fractures compared to their peers who underwent a physiological 
menopause. Finally, an increased risk for cognitive impairment, dementia and Parkinson 
disease, inversely proportional with age at menopause, was reported in premature 
menopausal women following oophorectomy (Rocca et al., 2007, 2008).  
4. Hormone replacement therapy  
4.1 Basis for the hormone replacement therapy in menopause  
When an installed hormonal deficiency generates symptoms in an individual, disturbing its 
well-being, it is expected that by adjusting the deficit, an improvement or even an offset of 
the symptoms should be reached (Wilson, [1966]).  That was the hypothesis guiding 
clinicians decisions about substitution of ovarian steroids in menopause. Hormone 
replacement therapy (HRT) has been a common practice during the last decades, being 
initially used for both treatment of symptoms and prevention of chronic medical conditions 
related to menopause (e.g. heart and bone diseases). But 2002, the year when the first results 
from a large randomized and placebo-controlled trial (the Women Health Initiative – WHI) 
were published, marked a major change in both clinicians and patients perception towards 
the use of HRT(Rossouw et al., 2002). Conducted with the aim of evaluating HRT major 
benefits and risks, WHI results contradicted previous observational studies and showed an 
increased risk for cardiovascular events together with that of breast cancer rates in the 
studied population. Even if this resulted in a significant reduction in the use of HRT 
worldwide (Hersh et al., 2004; Lagro-Janssen et al., 2010; MacLennan et al., 2004), it 
represented also the subject to some major controversies. One major debate is the legitimacy 
of applying these conclusions to all women, when most of the women concerned by HRT 
prescription belong to the 50-54 years age group while participants in the WHI study had an 
average age of 63 years and a high body mass index. Thus, following the release of the first 
WHI report, various studies intended to better evaluate the real risks and benefits associated 
with HRT were conducted. The resulting body of evidence has led to the necessity of 
periodic revision of the existing recommendations and statements in this field (North 
American Menopause Society (NAMS) position statement, 2010; Santen et al., 2010; Sturdee 
et al., 2011).  
4.2 Current recommendations 
Current recommendations specify that HRT use should be restricted mainly to moderate or 
severe menopausal symptoms alleviation. It should not be used as a mean of chronic disease 
prevention and it is advisable to restrict treatment administration to the shortest period and 
the lowest dosage possible to control symptoms effectively. Nevertheless, in selected cases, 
HRT may be used to treat or to reduce the risk of diseases (e.g. osteoporosis). This involves 
HRT use in prevention of further bone loss and/or reduction of osteoporotic fracture in menopausal 
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women when alternate therapies are not appropriate or cause side effects (NAMS position statement, 
2010) or for  women younger than 60 years, with an increased risk of fracture (Sturdee et al., 2011). In 
the particular case of women diagnosed with POI, HRT is recommended at least until the 
median age of natural menopause is reached (NAMS position statement, 2010).  
4.3 Hormone replacement therapy regimens  
4.3.1 Oestrogens and progestins in HRT 
HRT comprises a variety of regimens, compounds, dosages and routes of administration. In 
most women, excepting hysterectomized patients, menopausal treatment requires 
preparations combining oestrogens with a progestin, the latter being used mainly to balance 
oestrogen’s effects on the endometrium and to avoid endometrial hyperplasia and an 
increased risk of secondary carcinoma. This combination therapy may be administrated 
either in a sequential cyclic regimen or in a continuous one. The sequential regimen involves 
the alternation of a pure oestrogenic period to an oestro-progestative one, leading to 
withdrawal bleeding when the progestin administration is discontinued. This regimen is 
commonly administrated with a monthly cyclicity including at least 10 days of progestin 
treatment. Quarterly regimens are also available, involving progestin administration every 3 
months, although in this case the risk for endometrial hyperplasia needs further evaluation. 
The continuous combined treatment implies the administration of both compounds on a 
daily basis and uses lower doses of progestin compared to the sequential regimen. This 
constitutes an option especially in older women not desiring a monthly withdrawal 
bleeding, even if uterine bleeding with unpredictable onset may not be excluded 
particularly during the first administrations (Doren, 2000; Ylikorkala & Rozenberg, 2000). 
Available formulations for the estrogens and progestins in HRT and their commonly used 
doses are listed in Table 1. 
4.3.2 Other therapeutic options 
Androgens are thought to play a role in maintaining a normal libido and sexual function in 
postmenopausal women and to potentially prevent the decline of bone quality, muscular 
force and cognitive function. Thus, after exclusion of other possible causes, androgen 
therapy represents an option for menopausal women with hypoactive sexual desire disorder 
undergoing concomitant oestrogen treatment, especially in those who have suffered a 
surgical menopause (Davis et al., 2008).  
Tibolone is a synthetic compound with mixed oestrogenic, progestogenic and androgenic 
activities, representing an alternative to conventional HRT (Lazovic et al., 2008). It 
represents an efficient option for vasomotor symptoms alleviation or prevention of BMD 
loss in menopausal women (Gallagher et al., 2001; Swanson et al., 2006).  
Another possible option in menopausal therapy refers to the selective oestrogen receptor 
modulators (SERMs). These are pharmacologic agents characterised by variable oestrogen 
activity, acting as oestrogen agonists in some tissues while in other tissues they exert 
oestrogen antagonist effects. Examples of SERMs of interest in menopause treatment include 
raloxifene together with novel molecules like bazedoxifene, lasofoxifene or ospemifene.  
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Route Oestrogens Dosage 
Oral 
Conjugated estrogens  
(conjugated equine oestrogens) 
0.625 mg 
Micronized 17 beta oestradiol  1, 2 mg 
Oestradiol valerate 1, 2 mg 
Estropipate  
(piperazine estrone sulphate) 
0.75, 1.5, 3 mg 
Transdermal 
17 beta oestradiol (patch)   25, 37.5, 50, 75, 100 µg/day 
Oestradiol (gel) 1 mg/ 1g 
Subcutaneous Oestradiol (implant)  20, 50, 100 mg 
Vaginal 
Estriol (gel)  1mg/g 
Estradiol (tabs) 25µg 
 Progestins  
Oral 
Norethisterone acetate 0.5, 1 mg 
Medroxyprogesterone acetate 2.5, 5 mg 
Chlormadinone acetate 2, 5, 10 mg 
Drospirenone 2 mg 
Dydrogesterone 5, 10 mg 
Nomogestrol acetate 3.75, 5 mg 
Promegestone 0.125, 0.25, 0.5 mg 
Micronized progesterone 100, 200 mg 
Transdermal Levonorgestrel 7, 10µg/24h 
Intrauterine Levonorgestrel intrauterine device 20 µg/24h 
Table 1. Commonly used oestrogens and progestins 
4.4 Primary ovarian insufficiency: Particular requirements 
Current publications highlight the lack of specifically designed HRT regimens for women 
with POI and the fact that existing observations from studies conducted on older women 
undergoing natural menopause should not be extrapolated to the much younger category of 
POI women. In the absence of a consensus regarding the ideal hormonal replacement 
regimen for women facing a premature cessation of the ovarian function, the oestro-
progestative substitution commonly involves either HRT or combined oral contraceptive 
pills (COCP) prescription. Even if the use of the latter may be associated with a lower 
emotional impact for these patients, being perceived less as a treatment, it must be 
underlined that COCP standard preparations contain synthetic steroids in higher doses than 
the ones required for physiologic hormonal replacement in POI (Nelson et al., 2005). There is 
an urgent need to develop evidence-based guidelines relying on solid research in order to 
optimize the care of this group of women (Panay & Kalu, 2009). 
www.intechopen.com
 Pharmacology of Hormone Replacement Therapy in Menopause 
 
321 
4.5 Benefit versus risk of hormonal replacement therapy based 1 on the reviews of 
clinical studies 
Despite the wide agreement that hormonal substitution remains the most effective option 
for the alleviation of menopausal symptoms, a careful evaluation of the benefit-risk balance 
is however essential prior to prescribing a HRT regimen because of its associated risks 
(Santen et al., 2010). The principal benefits and risks related to HRT in the light of recent 
evidences are further discussed in this paragraph.  
The cardiovascular events represent the first cause of mortality in postmenopausal 
women and constituted a major subject of controversy regarding the use of HRT, an 
uncertainty accentuated by the discrepant results between randomised controlled trials 
(RCTs)  (Hulley et al., 1998; Rossouw et al., 2002; Vickers et al., 2007) and observational 
studies (Bush et al., 1987; Grodstein et al., 1997; Stampfer et al., 1991). Initially, as 
expected from the physiological functions of oestrogens, several observational studies 
suggested a protective role of HRT on the cardiovascular system. Contrary to these 
observations, the WHI, a randomised, placebo-controlled trial, failed to validate the 
cardioprotective effect of HRT. The primary outcome of this study was related to the 
effects of menopausal substitution on the cardiovascular function and breast cancer risk, 
participants receiving either conjugated equine estrogens (CEE) alone (0.625mg/day) if 
hysterectomised (Anderson et al., 2004) or 0.625mg/day CEE in combination with 
2.5mg/day medroxyprogesterone acetate (MPA) if they presented with an intact uterus 
(Rossouw et al., 2002). In an attempt to explain the disparity between these results the 
“timing hypothesis” arose as a possible answer, supported by differences between women 
enrolled in this study and those participating in observational studies (Grodstein et al., 
2003). Thus, while the former included women more than a decade away from the onset 
of menopause, in the latter HRT was usually initiated shortly after menopause. Animal 
studies supported this hypothesis and demonstrated that the positive cardiovascular 
effects of hormonal substitution are inversely correlated with the delay of initiating the 
treatment (Clarkson, 2007). Several analysis, including some of the WHI subgroup data, 
tested the timing hypothesis and showed a trends towards a decreased risk in women 
younger and closer to menopause (Rossouw et al., 2007; Salpeter et al., 2006). Trials 
addressing specifically the effects of HRT in younger women (e.g. 
Kronos EarlyEstrogen Prevention Study (KEEPS) (Harman et al., 2005), Early Versus Late 
Intervention Trial With Estradiol (ELITE, NCT00114517) are currently under way and 
their results will probably shed a better light on these controversial facts. 
Venous thromboembolism (VTE) is one of the major harmful effects of hormone therapy 
use among postmenopausal women (Olie et al., 2010). A recent meta-analysis on the risk of 
VTE in women using HRT indicated an increased risk by twofold to threefold when oral 
oestrogens were administrated (the combined relative risk (RR) from both trials and 
observational studies of 1.9 and confidence interval (CI) of 1.3 to 2.3, with a higher risk 
within the first year of treatment (Canonico, Plu-Bureau et al., 2008). When VTE risk was 
analysed in women receiving transdermal oestrogen, there was a combined RR of 1.0 (CI, 0.9 
- 1.1). The impact of the route of administration on VTE risk and the recent pharmacogenetic 
studies providing support for the implication of the first pass effect in these different 
outcomes are detailed in chapter 5.  
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Musculoskeletal effects. Both observational studies (Cauley et al., 1995; Grodstein, 
Stampfer et al., 1999; Kiel et al., 1987) and RCTs (Cauley et al., 2003; Jackson et al., 2006; 
Lindsay et al., 2005) have proven HRT efficacy in reducing bone loss in menopausal women. 
Additionally, this positive effect appears to be present even when lower doses of oestrogen 
are used (Lindsay et al., 2005). However, rapidly after its discontinuation the protective 
effect on BMD is no longer evident. A recent study, evaluating hip fracture incidence after 
HRT cessation in a large cohort of 80.955 postmenopausal women, reported a significantly 
increased risk of hip fracture within only two years following HRT cessation compared to 
women who continued using HRT (Karim et al., 2011).  
HRT and cancer risks. There is a large body of studies investigating the association 
between HRT and the risk for various types of cancer, primarily those hormone-
dependent and particularly breast cancer. Breast cancer was one of the reasons for the 
premature discontinuation after 5.2 years of follow-up of the arm receiving combined 
HRT in the WHI trial, as the increased risk in breast cancer exceeded the stopping 
boundary for this adverse effect (RR 1.26; 95% CI 1.00-1.59) (Rossouw et al., 2002). 
Contrary to these findings, in the oestrogen-only group the relative risk was inferior 
compared to the control group (RR 0.77, 95% CI 0.57–1.06) (Anderson et al., 2004), 
suggesting that in addition to oestrogen, progestins have also a role in breast cancer 
pathophysiology. The risk of developing breast cancer increases with longer duration of 
HRT use (Beral, 2003; Fournier et al., 2008).  One meta-analysis assessing the impact of 
HRT on the risk of  invasive breast cancer in epidemiological studies and RCTs reported 
an increased annual risk for breast cancer varying between 0–9% in the case of E+P 
regimens and 0–3% in oestrogen-only administration (Greiser et al., 2005).  
Although the risk of CHD was reported to increase when HRT is started a long time after 
the onset of menopause, the reverse situation seems to apply in the case of breast cancer. 
Data from the WHI trial supported this so called “gap time hypothesis” and reported an 
increased risk for breast cancer when HRT is started less than 5 years after the onset of 
menopause in both E (with a RR of 1.12 versus 0.58 when HRT was initiated less than 5 and 
respectively more than 5 years from menopause in women without a prior HRT use, or a 
relative risk (RR) of 1.00 versus 0.77 in women with prior HRT use) and E+P arms (with a 
RR of 1.77 versus 0.99 when HRT was initiated less than 5 and respectively more than 5 
years from menopause in women without a prior HRT use, or a RR of 2.06 versus 1.30 in 
women with prior HRT use)(Prentice et al., 2009). The fact that ER positive breast tumours 
in postmenopausal women, but not in premenopausal ones, respond to treatment with high-
dose oestrogen further supports this hypothesis and suggests that the decline in oestrogen 
levels associated with menopause may sensitize breast cancer cells to the proapoptotic 
effects of estrogen (Taylor & Manson, 2011).  
Endometrial cancer (EC) constitutes another adverse effect linked to HRT use. The most 
common form of EC, the endometrioid (type I) variant, is generally hormonally 
responsive and women with an unbalanced oestrogen exposure are at increased risk for 
this form of EC. No risk increase was reported in women using a continuous combined 
HRT regimen, while the use of sequential HRT resulted in different risk profiles according 
to the duration of treatment (Jaakkola et al., 2011). Thus, when used for less than 5 years, 
the sequential E+P regimen showed a decreased risk for EC (RR 0.67, 95% CI 0.52-0.86), 
while continuing treatment after 5 years resulted in an increased risk for EC (RR 1.11, 
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95%CI 0.87-1.41 for the 5-10 years interval and RR 1.38, 95%CI 1.15-1.66 for an use 
exceeding 10 years). 
Several studies reported an increased risk for ovarian cancer in women using HRT (Beral et 
al., 2007; Morch et al., 2009), with a stronger association in the case of unopposed oestrogen 
administration (Hildebrand et al., 2010). However, due to the small excess risk, the overall 
benefit-risk balance in HRT appears not to be significantly influenced by these results 
(Taylor & Manson, 2011).  
Colorectal cancer. Observational studies have suggested an association between the use of 
HRT and a reduced incidence in colorectal cancer (Grodstein, Newcomb et al., 1999), an 
observation also validated by data from the E+P arm from the WHI trial (Chlebowski et al., 
2004). However, despite a reduced overall rate, poor prognosis forms of colon cancer were 
diagnosed more frequently in women receiving HRT than in the placebo group. In contrast 
to the group receiving E+P, the reduced incidence of colorectal cancer was not found in the 
oestrogen-alone arm of WHI (Ritenbaugh et al., 2008). The relation between colorectal 
cancer and hormone exposure is further complicated by recent evidences suggesting that a 
greater endogenous estrogen exposure may increase the risk of colorectal cancer in 
postmenopausal women (Clendenen et al., 2009; Zervoudakis et al., 2011).  
Finally, results from several studies comprising those of WHI (Chlebowski et al., 2009) have 
led to the inclusion of lung cancer on the list of potential adverse effects of HRT, although a 
neutral effect of HRT on lung cancer risk (Ayeni & Robinson, 2009) or even lower risks 
(Rodriguez et al., 2008) have been reported by others. Post-hoc analysis of WHI showed 
than even if the incidence of lung cancer in women using HRT did not increase, the number 
of death from lung cancer was significantly higher (in particular deaths from non-small-cell 
lung cancer) in women receiving combined HRT (Chlebowski et al., 2009), contrary to the 
use of oestrogen alone where the death rates were similar to the control group (Chlebowski 
et al., 2010).  
The effect of HRT on a variety of conditions (e.g. mood disturbances, neurocognitive 
impairment, gallbladder disease, immune disorders, etc) have also been investigated. 
However, as either current evidences are insufficient or their impact on the overall benefit-
risk balance is not significant, we will not detail them.   
Particularities of the HRT benefit-risk balance in POI patients. Available results from 
studies evaluating HRT effects, especially its risks, do not address particularly the 
population of POI patients, but rather there is a tendency to apply to this group an 
extrapolation of findings from natural menopause, although there are evident differences in 
the HRT benefit-risk ratio between the two populations.  
Cardiovascular and breast cancer risks, the two main adverse effects related to HRT use, 
need a special consideration in the context of women diagnosed with POI. First, the “timing 
hypothesis” for cardiovascular effects of HRT suggest a clear trend towards cardiovascular 
benefits in young women using HRT and hence, it is possible that the benefits in the 
younger POI patients might be even greater (Panay & Fenton, 2008). Secondly, the breast 
cancer risk profile differs in women undergoing a premature menopause compared to the 
general population. A younger age at menopause is protective against breast cancer 
regardless of whether the menopause was natural or surgical (Hulka & Moorman, 2008). 
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Thus, POI patients should be informed that results from reports on HRT associated breast 
cancer do not necessarily apply to their case, in which treatment is intended to provide the 
hormones that should be physiologically present at their age (Maclaran & Panay, 2011).  
These particularities of the HRT risk profile in women facing a premature cessation of the 
ovarian function, together with the beneficial bone effects (Farquhar et al., 2009), support the 
current recommendations regarding the need for HRT substitution until the average age of 
natural menopause (Vujovic et al., 2010).  
5. Pharmacology of hormone replacement therapy 
The pharmacology of hormone replacement therapy is of a particular interest given the 
complex benefit/risk balance and the importance of this treatment for women health. As 
illustrated in previous paragraphs, there is a wide diversity of drugs and protocols 
proposed for HRT. Our analysis will be limited to the pharmacology of the natural sex 
steroid 17┚-estradiol.  
5.1 The route of oestradiol administration (oral versus transdermal) highlights the 
hepatic first pass effect 
Oral oestradiol is commonly used by women receiving HRT, being seen as a convenient and 
inexpensive option. In turn, following oral administration, oestradiol is subject to the first-
pass effect, a term that encompasses the metabolic changes underwent by a drug before it 
reaches systemic circulation. This results in the use of higher doses of oestradiol (~ 1,5 
mg/day) compared to parenteral routes (patch ~ 50µg/24h). Moreover, subsequent to the 
various metabolic changes suffered by oestrogens once absorbed in the intestinal tract, a 
specific profile of oestradiol metabolites and oestrogen-dependent serum parameters with 
particular pathophysiological implications will appear, widely different from what is 
observed after the use of transdermal oestradiol where the first-pass effect is avoided.  
The oestradiol metabolism pathway (Raftogianis et al., 2000) is outlined in Figure 4. Rapidly 
after the intestinal absorption, part of oral oestradiol is converted to oestrone, a reversible 
reaction catalysed by 17┚-hydroxysteroid-dehydrogenase (HSD), and the conversion may 
continue towards their inactive conjugates (i.e. sulfates and glucuronides). Subsequent to 
this process, the oestrone/ oestradiol ratio resulting from oral administration is significantly 
higher (approximately 5:1) than the one observed following transdermal administration 
(approximately 1:1, which is similar to the physiologic ratio found in premenopausal 
women)(Kuhl, 2005). Contrary to the aforementioned transformations, further phase I 
reactions (oxidation reactions catalysed by cytochrome P450 (CYP) enzymes) are no more 
reversible. The final steps in oestrogen metabolism involve the process of detoxification 
under the action of phase II enzymes.  
The first pass effect of oestradiol results in various biological consequences (De Lignieres et 
al., 1986). For instance, a well known effect attributed to hepatic first pass is the decrease of 
IGF-1 after oral oestradiol, whereas no significant change was observed with transdermal 
oestrogens  (Sonnet et al., 2007). Furthermore, an increased synthesis of blood coagulation 
factors (Caine et al., 1992) and resistance to activated protein C (Oger et al., 2003) constitute 
another important consequences which are directly implicated in VTE pathophysiology, one 
of the major adverse events of oral oestrogens.  
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Various isoforms of cytochromes P450s (CYP3A, CYP1A and CYP1B families) activate estrogens during phase-1 
metabolism. Oxidative metabolites, such as hydroxyestradiol and quinone derivatives, are conjugated by various 
phase-2 enzymes. The expression of several of these enzymes (SULTs, UGTs, GSTs and NQO1) is regulated by 
Nrf2. E: estradiol or estrone; CYPs: cytochrome P450s; UGTs: UDP-glucuronosyltransferase; COMT: catechol-o-
methyltransferase; GSTs: glutathione S-transferases; NQO1: NAD(P)H dehydrogenase, quinone 1. Phase-1 
metabolism is represented by horizontal arrows. Phase-2 metabolism is represented by vertical arrows (dashed).  
Fig. 4. Oestrogens hepatic metabolism 
5.2 Pharmacokinetic of oral versus transdermal oestrogens 
The pharmacokinetics of exogenous estrogens is complex and most efficacy studies of 
transdermal versus oral oestrogens have not included the measurement of oestrogens 
concentrations. The oral route of oestradiol administration is easy and convenient, however 
the hormone is  extensively metabolized in the gut and the liver leading to first-pass effect 
and, as previously mentioned, to a high estrone/oestradiol ratio (Kuhl, 2005). On the other 
hand, transdermal 17┚-oestradiol is well absorbed through the epidermis and produces 
higher parent oestrogens serum concentrations and lower metabolites ratios because it 
bypasses the liver. Moreover, owing to a very low bioavailability [0.1 – 12%] of oral 
micronized 17┚-oestradiol (O'Connell, 1995), higher doses are needed for the oral route 
compared to transdermal administration (O'Connell, 1995; Powers et al., 1985).  
Pharmacokinetic profiles of transdermal and oral oestradiol are very different with oral 
administration producing fluctuant concentrations compared to the more constant levels 
achieved with transdermal formulations (Kopper et al., 2009). Interestingly, there is no 
pharmacokinetic/pharmacodynamic relationship between serum levels and positive effects 
of oestradiol treatment. It has been clearly shown that serum level after transdermal 
oestradiol does not predict the outcome when treating hot flushes (Steingold et al., 1985). 
The precise oestradiol and oestrone concentrations required to prevent bone loss and 
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cardiovascular disease after either oral or transdermal oestrogen administration are also 
unknown (O'Connell, 1995).  
5.3 Venous thromboembolism risk and HRT 
As previously mentioned, VTE represents one of the main adverse effects of HRT in 
postmenopausal women (Canonico, Plu-Bureau et al., 2008; Cushman et al., 2004). Yet, while 
oral oestrogen was associated with a significantly increased risk for VTE, this was not 
observed in women treated with transdermal oestrogen (Canonico et al., 2010; Canonico et 
al., 2007; Olie et al., 2010; Scarabin et al., 2003; Straczek et al., 2005). An explanation for the 
distinct VTE risk profile following the two routes of administration involves the first-pass 
effect of oestrogen. This was shown to affect the synthesis of various oestrogen-dependent 
hepatic serum factors (Kuhl, 2005), including coagulation and fibrinolysis factors, resulting 
in blood coagulation activation (Scarabin et al., 1997; Vehkavaara et al., 2001), increased 
thrombin generation (Scarabin et al., 2011) or induction of resistance to activated protein C 
(Hemelaar et al., 2006; Oger et al., 2003). However, the precise mechanisms by which these 
changes occur are still unclear.  
5.4 Pharmacogenetics: Genetics factors predisposing to venous thromboembolism 
(VTE) after oral oestradiol 
Straczek et al. investigated the impact of the route of oestrogen administration on the 
association between a prothrombotic mutation (factor V Leiden or prothrombin G20210A 
mutation) and VTE risk. This study confirms the increase risk of VTE due to oral 17┚-
oestradiol in women presenting a genetic predisposition to VTE (Straczek et al., 2005). On 
the other hand, we have recently suggested that the hepatic metabolism of oestrogen may 
modulate the risk of VTE either through an increased phase I metabolism or through a 
decreased phase II metabolism. To address this important question, we have tested genetic 
polymorphisms capable to modulate oestradiol phase I or phase II liver metabolism. These 
polymorphisms do not increase the risk of VTE in the absence of HRT. First, we have 
demonstrated that increased expression of CYP3A5, a phase I enzyme of particular interest 
in oestrogen liver metabolism, in women carrying the CYP3A5*1 allele, is associated with a 
higher risk of VTE during oral oestrogen administration (RR 14.5; CI 2.8  - 73.9), without 
observing the same interaction in women receiving transdermal oestrogen  (Canonico, 
Bouaziz et al., 2008). Further, we have investigated the association between VTE and nuclear 
factor (erythroid-derived 2)-like 2 (NFE2L2) polymorphisms (Bouligand et al., 2011). 
NFE2L2 gene encodes for a transcription factor also known as Nrf2 (NF-E2 related factor 2), 
essential for both maintenance and induction of phase II metabolism (Thimmulappa et al., 
2002). One functional polymorphism (rs6721961) from the promoter region of NFE2L2 was 
described to be associated with an impaired auto-induction of this transcription factor 
(Marzec et al., 2007). The presence of this polymorphism may subsequently alter the 
expression of phase II genes, including those essential for the detoxification of oestrogen 
metabolites (see Figure 5) (Raftogianis et al., 2000). Our post-hoc analysis of the ESTHER 
Study (Canonico et al., 2007; Scarabin et al., 2003; Straczek et al., 2005) demonstrated the 
association between VTE risk and the NFE2L2 polymorphism (i.e. rs672196) in oral 
oestrogen users (RR 17.9; CI 3.7 – 85.7).  
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Fig. 5. Genetic polymorphisms modulating liver metabolism and first pass effect of 
oestrogens. 
These pharmacogenetic studies provide new insights suggesting that liver metabolism of 
oestrogens may be implicated in the pathophysiology of VTE among women using HRT 
with oral oestrogen therapy. This original finding deserves further investigations in largest 
and independent series of women receiving oral 17┚-oestradiol as well as other oestrogens 
with different metabolic pathways, not only to treat postmenopausal symptoms but also for 
contraception. Taking into account the proportion of women using exogenous hormone 
therapy, these new results may have important clinical implications to improve the 
stratification of thrombotic risk and identify new groups at high risk.  
6. Conclusion  
The increasing life expectancy observed during the last century, without an equivalent 
change in the average age of menopause, resulted in an increased number of women facing 
the effects of low ovarian steroids for a longer period of time. Thus, the high interest 
towards therapeutic options capable to alleviate menopausal symptoms and the extensive 
research in this field are not surprisingly. Despite the current controversies summarised 
here which encompass HRT use, further researches will likely improve therapeutic 
outcomes. In this context, pharmacogenetics studies play a key role in fulfilling the aim of 
providing patients with an individualised therapy which will reduce risks and improve 
benefits related to HRT. 
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